Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Beyond p-values: When does clinical impact outweigh statistical significance?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.02.20
Views: 877
Rating:

Prof Matthew Sydes - University College London, London, UK

Prof Matt Sydes speaks to ecancer at the 2020 ASCO GU meeting in San Francisco.

He explains the importance of contextualising statistical data to identify clinically relevant results and addresses the debate of clinical significance versus statistical significance.

Prof Sydes describes the interpretation of the radiotherapy comparison conducted in patients with metastatic prostate cancer in the STAMPEDE trial.

He also explains how to carry out an accurate sample size calculation and how to choose the right outcome measures for prostate cancer trials.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Clinical significance versus statistical significance
The STAMPEDE trial
The HORRAD trial
Calculating sample size
Choosing the right outcome measures
The COMET initiative
Investigating the combination of zoledronic acid and celecoxib in the STAMPEDE trial

 

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation